India's CRDMO sector is projected to reach US$ 25 billion by 2035, driven by cost advantages, fast project startups, and growing biologics expertise, strengthening its global pharma innovation role.

WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that it has again passed the GMP inspection by Japan's ...

The debate on MSCs, mesenchymal stromal cells versus mesenchymal stem cells, continued for more than two decades (since 2006), being the major obstacle for MSCs study and clinical application. The ...